ultram tramadol hydrochloride

prescriptions for adipex

PARIS, July 02, 2009 /PRNewswire-FirstCall/ --Sanofi-aventis announced today that the U., Professor of Medicine & Director, Division of Cardiology, McMaster University, Hamilton, Canada, and co-principal investigator in the ATHENA study. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash. Multaq is also contraindicated in second- or third-degree atrioventricular (AV) block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), bradycardia <50 bpm, QTc Bazett interval greater than or equal to 500 ms and severe hepatic impairment. ultram tramadol hydrochloride "Sanofi-aventis is proud of its ability to bring innovative therapies to market and contribute to reducing the public health burden of atrial fibrillation. The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance. ultram tramadol hydrochloride " The landmark ATHENA trial evaluated the efficacy and safety of Multaq in patients with AF/AFL or a recent history of these conditions (71% of these patients had no heart failure, 29% were in NYHA class I-III with stable heart failure). what is the medicine tramadol

S. "We are pleased that the FDA has granted approval of Multaq for patients in a therapeutic area that has seen few new treatment options in the last twenty years," said Marc Cluzel, MD, Senior Vice President, Research and Development, sanofi-aventis." The incidence of atrial fibrillation is growing worldwide in relation to aging populations. The patients enrolled in ANDROMEDA had relatively severe heart failure and had been hospitalized, or referred to a specialty heart failure clinic for worsening symptoms.us/Multaq/Multaq. ultram tramadol hydrochloride LLC also announced the launch of mPACT(TM) - Multaq Partnership for Appropriate Care and Treatment - the Risk Evaluation and Mitigation Strategy (REMS) developed by sanofi-aventis U. Sanofi-aventis is listed in Paris and in New York . ultram tramadol hydrochloride 001) compared with placebo meeting the primary endpoint.S. gg 414 xanax

To ensure the use of Multaq in the appropriate patient population, sanofi-aventis U.S. Patients were predominantly NYHA II and III (New York Heart Association classification) and only 25% had a history of AF/AFL at randomization. The ANDROMEDA and ATHENA trials were published in the New England Journal of Medicine (NEJM) respectively in 2008 and 2009. In a placebo-controlled study in patients with severe heart failure requiring recent hospitalization or referral to a specialized heart failure clinic for worsening symptoms (the ANDROMEDA study), patients given dronedarone had a greater than two-fold increase in mortality. ultram tramadol hydrochloride Patients taking Multaq had higher rates of diarrhea, nausea, bradycardia, QT-interval prolongation and cutaneous rash than patients taking placebo. and represents one-third of hospitalizations for arrhythmia in Europe. ultram tramadol hydrochloride The patient population enrolled in the ANDROMEDA and ATHENA studies was significantly different. The ANDROMEDA and ATHENA trials were published in the New England Journal of Medicine (NEJM) respectively in 2008 and 2009.